Engineered human extracellular dnase enzymes for drug candidate selection
AssigneeNeutrolis, Inc.
InventorTobias A. FUCHS
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a library of engineered DNASE proteins (including DNASE1, DNASE1-LIKE 1, DNASE1-LIKE 2, DNASE1-LIKE 3, DNASE2A, DNASE2B) that allows to select drug candidates for developing therapeutics for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In accordance with the invention, the selected DNase variant has improved properties, including properties amenable to clinical development, including manufacturing, toxicology, pharmacokinetic, and/or use in therapy.
Claims111
A method for making a DNASE therapeutic composition for treating a disorder associated with pathological levels of extracellular chromatin or NETs, the method comprising:
- evaluating a plurality of extracellular DNASE variants having building block substitutions and/or half-life extension moiety for one or more characteristics selected enzymatic activity, nucleic acid substrate preference, potential for recombinant expression in prokaryotic or eukaryotic host cells, immunogenic potential in humans and animals, and pharmacodynamics in animal models;
- selecting a DNASE variant having a desired enzymatic, physical, immunological and/or pharmacodynamics profile, and
- formulating the selected DNASE variant for administration to a patient.
A DNASE variant or pharmaceutical composition thereof, the DNASE variant comprising one or more building block substitutions and/or an N-terminal fusion of human albumin and a linker amino acid sequence.
Dependencies are inferred from the claim text.